This article needs editing to comply with Wikipedia's Manual of Style. In particular, it has problems with not using MEDMOS. (July 2018) |
| Cholinergic urticaria | |
|---|---|
| CU on the volar aspect of the forearm | |
| Specialty | Dermatology |
| Symptoms | Tiny "itchy" wheals and small papular bumps on a reddish background. |
| Causes | Unclear (triggered by heat) |
| Treatment | Medications, sweat therapy |
Cholinergic urticaria (CholU, CU) is a chronic, inducible form of hives (urticaria) that is triggered by an elevation in body temperature, breaking a sweat, or exposure to heat. It is also sometimes called exercise-induced urticaria or heat hives. The condition is caused by an overreaction of the immune system to the release of histamine and other chemicals in response to the increase in body temperature. This results in the characteristic red, itchy, and sometimes raised bumps or welts on the skin that are associated with hives.
Cholinergic urticaria typically presents with a number of small papular hives all over the body, that involve cutaneous inflammation (wheals) and severe nerve pain, which usually develops in response to exercise, bathing, staying in a heated environment, spicy foods, or emotional stress. Symptoms may also include respiratory symptoms, angioedema, or anaphylaxis. The symptoms subside and manifest rapidly on and off throughout the day with no notice, typically going away within an hour. Cholinergic urticaria may significantly impair quality of life, especially in relation to normal day-to-day activities. It is caused by an overreaction of the immune system to the release of histamine, mast cells, and other chemicals in response to the small nerve fibers throughout the body due to the increase in body temperature being allergic to sweat.
This section needs expansion. You can help by adding missing information. (April 2026) |
As of 2023[update], subtypes of the condition are still being determined. A 2023 review article in the American Journal of Clinical Dermatology lists four subtypes:
This subtype of CU refers to those who are hypersensitive to their own sweat.
Diagnosis is made by injecting autologous (the person's own) sweat into the skin.
The hives are observed to coincide with perspiration points of sweating.
Tanaka et al. found that the sweat hyper-sensitivities of CU and atopic dermatitis seem to be virtually the same, and therefore, the sweat-induced histamine release from basophils may also be mediated by a specific IgE for sweat in atopic dermatitis as well as CU.
This subtype of CU refers to those who have abnormally reduced sweating. Forced perspiration by excessive body warming (hot bath or exercise) used daily may reduce the symptoms through exhaustion of inflammatory mediators.
Sweat is readily visualized by a topical indicator such as iodinated starch or sodium alizarin sulphonate. Both undergo a dramatic colour change when moistened by sweat. A thermoregulatory sweat test evaluates the body's response to a thermal stimulus by inducing sweating through the use of a hot box or room, thermal blanket or exercise. Failure of the topical indicator to undergo a colour change during thermoregulatory sweat testing can indicate anhidrosis and/or hypohidrosis (see Minor test).
A skin biopsy may reveal cellular infiltrates in sweat glands or ducts.
Severe heat intolerance (e.g., nausea, dizziness, and headache), and tingling, pricking, pinchy or burning pain over the entire body on exposure to hot environments or prolonged exercise which improve after cooling the body. Occurs in the absence of any causative skin, metabolic, or neurological disorders.

The wheals, hypohidrosis, and pain seems to result from the low expression levels of acetylcholinesterase (AchE) and cholinergic receptor, muscarinic 3 (CHRM3) in the eccrine gland epithelial cells.
Elevated expression levels of CCL2/MCP-1, CCL5/RANTES and CCL17/TARC which result in chemoattracted CD4+ and CD8+ T cell populations to the surrounding area may be responsible for exerting a downmodulatory effect on the AchE and CHRM3 expressions.
Corticosteroid inhibits the expressions of CCL2/MCP-1, CCL5/RANTES and CCL17/TARC. This further support the notion that CCL2/MCP-1, CCL5/RANTES and CCL17/TARC play a crucial role.
Although overall research is limited, several studies suggest that CU is relatively common, with reported prevalence rates ranging from 5% to 20% among urticaria case (depending on locale, race, and age). The condition is more common in young adults, and prevalence appears to peak in adults aged 26–28 (up to 20%). The vast majority of cases are reported to be mild, and proportionally few individuals seek medical attention regarding the condition.[citation needed]
Cholinergic urticaria was first described by Duke in 1924 as "urticaria calorica". The term cholinergic is derived from the finding that hives similar to those of CU can be evoked using cholinergic agonists (e.g. methacholine).